TrialBlood2015

Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma.

Shaji K Kumar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.